Department of Haematology, Cambridge University, Cambridge, United Kinigdom.
Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S151-60. doi: 10.1016/j.bbmt.2011.11.011.
Since the advent of next-generation sequencing (NGS) in 2005, there has been an explosion of published studies employing the technology to tackle previously intractable questions in many disparate biological fields. This has been coupled with technology development that has occurred at a remarkable pace. This review discusses the potential impact of this new technology on the field of blood and marrow stem cell transplantation. Hematologic malignancies have been among the forefront of those cancers whose genomes have been the subject of NGS. Hence, these studies have opened novel areas of biology that can be exploited for prognostic, diagnostic, and therapeutic means. Because of the unprecedented depth, resolution and accuracy achievable by NGS, this technology is well-suited for providing detailed information on the diversity of receptors that govern antigen recognition; this approach has the potential to contribute important insights into understanding the biologic effects of transplantation. Finally, the ability to perform comprehensive tumor sequencing provides a systematic approach to the discovery of genetic alterations that can encode peptides with restricted tumor expression, and hence serve as potential target antigens of graft-versus-leukemia responses. Altogether, this increasingly affordable technology will undoubtedly impact the future practice and care of patients with hematologic malignancies.
自 2005 年下一代测序（NGS）问世以来，利用该技术解决许多不同生物学领域以前难以解决的问题的已发表研究呈爆炸式增长。与此同时，技术发展也在以惊人的速度进行。这篇综述讨论了这项新技术对血液和骨髓干细胞移植领域的潜在影响。血液恶性肿瘤一直是那些其基因组成为 NGS 研究对象的癌症的前沿领域。因此，这些研究开辟了新的生物学领域，可以用于预后、诊断和治疗手段。由于 NGS 可实现前所未有的深度、分辨率和准确性，因此该技术非常适合提供有关控制抗原识别的受体多样性的详细信息；这种方法有可能为理解移植的生物学效应提供重要的见解。最后，进行全面的肿瘤测序能够系统地发现可编码具有限制肿瘤表达的肽的遗传改变，因此可作为移植物抗白血病反应的潜在靶抗原。总之，这项日益负担得起的技术无疑将影响血液恶性肿瘤患者的未来治疗和护理。
